As for efficacy, newer TKIs, such as dasatinib, radotinib, bosutinib, nilotinib and ponatinib, showed higher efficacy than imatinib in the first-line treatment of CP-CML patients, but the traditional treatment, such as IFN-α and Ara-C, suggested significantly lower efficacy when compared to TKIs. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.